Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science

Thumbnail image of item number 1 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 2 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 3 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 4 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Showing 1-4 of 14 pages in this article.

PDF Version Also Available for Download.

Description

This article argues against the treatment of Attention deficit/hyperactivity disorder (ADHD) with stimulant medication and behavior therapy, which are also typically reimbursed by healthcare insurers. Evidence suggests that these treatments fail to result in sustained benefit for the vast majority of children who receive them as demonstrated in the NIMH-funded MTA Cooperative study, the gold standard study in ADHD treatment effectiveness research. The authors instead look at the use of neurofeedback which is uniquely suited to treat the neuronal dysregulation that is common in people diagnosed with ADHD. However, healthcare insurers do not regularly cover this treatment method, so the … continued below

Physical Description

14 p.

Creation Information

Pigott, H. Edmond; Bodenhamer-Davis, Eugenia; Davis, Richard E. & Harbin, Henry August 23, 2016.

Context

This article is part of the collection entitled: UNT Scholarly Works and was provided by the University of North Texas to the UNT Digital Library, a digital repository hosted by the UNT Libraries. More information about this article can be viewed below.

Who

People and organizations associated with either the creation of this article or its content.

Authors

Publisher

Provided By

University of North Texas

Established in 1890, the University of North Texas has grown to be one of the nation's largest public research universities. Offering more than 200 degree programs, the university honors diversity, caring, creativity, and innovation in order to empower students to thrive in a rapidly changing world.

About | Browse this Partner

Contact Us

Corrections Questions

What

Descriptive information to help identify this article. Follow the links below to find similar items on the Digital Library.

Titles

  • Main Title: Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science
  • Alternate Title: Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat ADHD: It Will Take Clinician Action in Addition to the Compelling Science

Degree Information

Description

This article argues against the treatment of Attention deficit/hyperactivity disorder (ADHD) with stimulant medication and behavior therapy, which are also typically reimbursed by healthcare insurers. Evidence suggests that these treatments fail to result in sustained benefit for the vast majority of children who receive them as demonstrated in the NIMH-funded MTA Cooperative study, the gold standard study in ADHD treatment effectiveness research. The authors instead look at the use of neurofeedback which is uniquely suited to treat the neuronal dysregulation that is common in people diagnosed with ADHD. However, healthcare insurers do not regularly cover this treatment method, so the authors direct readers to resources to appeal insurers' denial of coverage for neurofeedback.

Physical Description

14 p.

Source

  • Journal of Neurotherapy, 17(2), International Society for Neurofeedback and Research, August 23, 2016, pp. 1-14

Language

Item Type

Identifier

Unique identifying numbers for this article in the Digital Library or other systems.

Publication Information

  • Publication Title: Journal of Neurotherapy
  • Volume: 17
  • Issue: 2
  • Page Start: 93
  • Page End: 105

Collections

This article is part of the following collection of related materials.

UNT Scholarly Works

Materials from the UNT community's research, creative, and scholarly activities and UNT's Open Access Repository. Access to some items in this collection may be restricted.

About | Browse this Collection

What responsibilities do I have when using this article?

Digital Files

When

Dates and time periods associated with this article.

Creation Date

  • August 23, 2016

Added to The UNT Digital Library

  • Aug. 3, 2020, 3:07 p.m.

Description Last Updated

  • Dec. 8, 2023, 1:31 p.m.

Usage Statistics

When was this article last used?

Yesterday: 0
Past 30 days: 0
Total Uses: 6
More Statistics

Interact With This Article

Here are some suggestions for what to do next.

Start Reading

Thumbnail image of item number 1 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 2 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 3 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.
Thumbnail image of item number 4 in: 'Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science'.

PDF Version Also Available for Download.

Citations, Rights, Re-Use

International Image Interoperability Framework

IIF Logo

We support the IIIF Presentation API

Links for Robots

Helpful links in machine-readable formats.

Archival Resource Key (ARK)

International Image Interoperability Framework (IIIF)

Metadata Formats

Images

URLs

Stats

Pigott, H. Edmond; Bodenhamer-Davis, Eugenia; Davis, Richard E. & Harbin, Henry. Ending the Evidentiary & Insurance Reimbursement Bias Against Neurofeedback to Treat Attention Deficit/Hyperactivity Disorder: It Will Take Clinician Action in Addition to the Compelling Science, article, August 23, 2016; (https://digital.library.unt.edu/ark:/67531/metadc1705550/: accessed May 31, 2024), University of North Texas Libraries, UNT Digital Library, https://digital.library.unt.edu; crediting University of North Texas.

Back to Top of Screen